Geode Capital Management, Llc reports 21.17% increase in ownership of 0TB / Theravance Biopharma, Inc.

Theravance Biopharma, Inc.

DE ˙ DB ˙ KYG8807B1068

13,90 € ↑0,30 (2,21%)

2026-06-05
DEL PRIS

Security	DE:0TB / Theravance Biopharma, Inc.
Institution	Geode Capital Management, Llc
Latest Disclosed Ownership	1,137,462 shares
Latest Disclosed Value	$ 18,462,688

On May 15, 2026 - Geode Capital Management, Llc filed a 13F-HR form disclosing ownership of 1,137,462 shares of Theravance Biopharma, Inc. (DE:0TB) valued at $15,014,498 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 938,724 shares of Theravance Biopharma, Inc.. This represents a change in shares of 21.17% during the quarter. The current value of the position is $15,810,722 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	1,137,462	198,738	21.17	18,463	5.10	0.0006
2026-02-09	2025-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	938,724	40,734	4.54	17,567	33.96	0.0011
2025-11-12	2025-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	897,990	4,007	0.45	13,113	32.96	0.0008
2025-08-08	2025-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	893,983	3,416	0.38	9,863	23.99	0.0007
2025-05-13	2025-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	890,567	27,765	3.22	7,955	-2.06	0.0006
2025-02-12	2024-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	862,802	4,823	0.56	8,121	17.42	0.0006
2024-11-12	2024-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	857,979	593	0.07	6,916	-4.88	0.0006
2024-08-09	2024-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	857,386	-110,066	-11.38	7,271	-16.21	0.0006
2024-05-13	2024-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	967,452	-26,548	-2.67	8,679	-22.33	0.0008
2024-02-13	2023-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	994,000	-67,177	-6.33	11,174	22.00	0.0012
2023-11-13	2023-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	1,061,177	-104,485	-8.96	9,159	-24.09	0.0011
2023-08-11	2023-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	1,165,662	-20,347	-1.72	12,065	-6.25	0.0014
2023-05-15	2023-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	1,186,009	45,256	3.97	12,868	107,133.33	0.0017
2023-02-13	2022-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	1,140,753	61,666	5.71	13	-99.89	0.0018
2022-11-14	2022-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	1,079,087	51,423	5.00	10,941	17.52	0.0017
2022-08-12	2022-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	1,027,664	17,501	1.73	9,310	-3.59	0.0014
2022-05-13	2022-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	1,010,163	-31,669	-3.04	9,657	-16.11	0.0012
2022-02-11	2021-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	1,041,832	346,328	49.80	11,512	123.71	0.0014
2021-11-12	2021-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	695,504	-236,764	-25.40	5,146	-61.98	0.0007
2021-08-13	2021-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	932,268	93,905	11.20	13,536	-20.89	0.0019
2021-05-12	2021-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	838,363	83,878	11.12	17,110	27.62	0.0026
2021-02-12	2020-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	754,485	16,390	2.22	13,407	22.86	0.0023
2020-11-13	2020-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	738,095	16,662	2.31	10,912	-27.94	0.0021
2020-08-13	2020-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	721,433	2,361	0.33	15,142	-8.88	0.0032
2020-05-14	2020-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	719,072	107,724	17.62	16,617	4.99	0.0043
2020-02-20	2019-12-31	13F/A-1	THERAVANCE BIOPHARMA	COM	G8807B106	611,348	-1,051	-0.17	15,827	32.68	0.0033
2020-02-13	2019-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	611,348	-1,051		15,827		2,017.0124
2019-11-12	2019-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	612,399	26,658	4.55	11,929	24.72	0.0028
2019-08-14	2019-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	585,741	41,712	7.67	9,565	-22.44	0.0023
2019-05-14	2019-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	544,029	46,805	9.41	12,333	-3.07	0.0032
2019-03-06	2018-12-31	13F/A-1	THERAVANCE BIOPHARMA	COM	G8807B106	497,224	46,003	10.20	12,723	-13.69	0.0039
2019-02-13	2018-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	497,224	46,003		12,723
2018-11-13	2018-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	451,221	16,500	3.80	14,741	49.52	0.0042
2018-08-14	2018-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	434,721	41,712	10.61	9,859	3.45	0.0030
2018-05-15	2018-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	393,009	19,533	5.23	9,530	-8.51	0.0031
2018-02-13	2017-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	373,476	13,217	3.67	10,416	-15.56	0.0035
2017-11-14	2017-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	360,259	6,709	1.90	12,335	-12.42	0.0046
2017-08-14	2017-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	353,550	23,270	7.05	14,085	15.83	0.0055
2017-06-21	2017-03-31	13F/A-1	THERAVANCE BIOPHARMA	COM	G8807B106	330,280	18,177	5.82	12,160	22.22	0.0050
2017-05-12	2017-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	330,280			12,160
2017-02-14	2016-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	312,103	46,103	17.33	9,949	3.22	0.0046
2016-11-10	2016-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	266,000	20,414	8.31	9,639	73.02	0.0049
2016-08-12	2016-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	245,586	52,347	27.09	5,571	53.39	0.0030
2016-05-13	2016-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	193,239	15,340	8.62	3,632	24.60	0.0019
2016-02-12	2015-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	177,899	8,698	5.14	2,915	56.89	0.0017
2015-11-13	2015-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	169,201	7,228	4.46	1,858	-11.86	0.0011
2015-08-14	2015-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	161,973	25,069	18.31	2,108	-11.24	0.0012
2015-05-14	2015-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	136,904	1,817	1.35	2,375	17.87	0.0014
2015-02-12	2014-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	135,087	3,327	2.53	2,015	-33.65	0.0012
2014-11-14	2014-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	131,760	1,925	1.48	3,037	-26.62	0.0020
2014-08-13	2014-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	129,835	129,835		4,139		0.0027

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.